Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (HKG:9989)

Market Cap	16.33B +13.2%
Revenue (ttm)	6.16B +2.1%
Net Income	432.46M -41.3%
EPS	0.29 -41.3%
Shares Out	n/a
PE Ratio	37.75
Forward PE	n/a
Dividend	0.27 (5.50%)
Ex-Dividend Date	May 26, 2025

Volume	477,000
Average Volume	319,175
Open	4.940
Previous Close	4.970
Day's Range	4.870 - 4.970
52-Week Range	4.400 - 7.260
Beta	0.45
RSI	45.26
Earnings Date	Apr 29, 2026

About HKG:9989

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Pharmaceutical preparations, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. The company offers pharmaceutical preparations products, such as enoxaparin sodium injection; API products, including heparin and enoxaparin sodium APIs. It also provides molecule biologics CDMO services, which include...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 2,150
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9989

Financial Performance

In 2025, HKG:9989's revenue was 5.48 billion, an increase of 3.75% compared to the previous year's 5.28 billion. Earnings were 349.49 million, a decrease of -45.96%.

Financial numbers in CNY